---
title: "Ghost Tickers: Nine U.S. Stocks Vanish From Regulatory View"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300554643.md"
description: "Nine obscure U.S. tickers show no regulatory filings or business disclosures since early 2026, raising concerns about OTC market transparency gaps and delisting process oversight."
datetime: "2026-09-30T10:14:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300554643.md)
  - [en](https://longbridge.com/en/news/300554643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300554643.md)
generator: "portal-rs"
---

# Ghost Tickers: Nine U.S. Stocks Vanish From Regulatory View

Nine U.S. tickers including XONE.US (XONE.US) and PDSB.US (PDSB.US) have vanished from mainstream financial databases, with no SEC filings or corporate announcements since Q1 2026. LVLU.US (LVLU.US) shows inactive trading patterns while RITRF.US (RITRF.US) lacks even basic company registration details. ELVA.US (ELVA.US) and AIRT.US (AIRT.US) appear in OTC markets but with zero revenue disclosures, and QCLS.US (QCLS.US)/PCLA.US (PCLA.US) investor portals returned error messages during verification. Notably, EYLD.US (EYLD.US) - labeled as an ETF - provides no holdings data despite its structure. Regulatory analysts suggest these may represent delisting candidates caught in administrative limbo, though the opacity challenges market surveillance frameworks.

### Related Stocks

- [XONE.US](https://longbridge.com/en/quote/XONE.US.md)
- [PDSB.US](https://longbridge.com/en/quote/PDSB.US.md)
- [LVLU.US](https://longbridge.com/en/quote/LVLU.US.md)
- [RITRF.US](https://longbridge.com/en/quote/RITRF.US.md)
- [ELVA.US](https://longbridge.com/en/quote/ELVA.US.md)
- [AIRT.US](https://longbridge.com/en/quote/AIRT.US.md)
- [QCLS.US](https://longbridge.com/en/quote/QCLS.US.md)
- [PCLA.US](https://longbridge.com/en/quote/PCLA.US.md)
- [EYLD.US](https://longbridge.com/en/quote/EYLD.US.md)

## Related News & Research

- [ELVA: Industry-leading battery safety and longevity drive global expansion and robust financial growth](https://longbridge.com/en/news/297071096.md)
- [PicoCELA Inc. GAAP EPS of -¥1046.43, revenue of ¥367.39M](https://longbridge.com/en/news/299486458.md)
- [PDS Biotech says Phase 2 study shows 39.3-month median survival for PDS0101 plus pembrolizumab in HPV16-positive head and neck cancer](https://longbridge.com/en/news/299763164.md)
- [Air T Expands Alerus Credit Facility to $25 Million, Adds Accordion and Extends to 2029](https://longbridge.com/en/news/298075021.md)
- [PDS Biotech prices up to USD 22.55 million PIPE led by Nant Capital](https://longbridge.com/en/news/298320373.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**